Liver-Directed Therapy for Hepatic Metastases in Patients Undergoing Pancreaticoduodenectomy
- 1 July 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Annals of Surgery
- Vol. 252 (1), 142-148
- https://doi.org/10.1097/sla.0b013e3181dbb7a7
Abstract
To analyze the perioperative and long-term outcomes of patients undergoing liver-directed therapy after pancreaticoduodenectomy in a large dual-center cohort of patients. Although aggressive liver-directed therapy may be beneficial, liver-directed therapy may be associated with a high risk of complications after pancreaticoduodenectomy. Of 5025 patients who underwent pancreaticoduodenectomy at the Johns Hopkins Hospital and the Mayo Clinic between 1970 and 2008, 126 (2.5%), patients were identified who were also treated with either simultaneous or staged liver-directed therapy. Data on demographics, primary tumor, and hepatic metastasis characteristics, as well as details of the liver-directed therapy were collected and analyzed. Primary tumor histology included neuroendocrine carcinoma (34.9%), pancreatic ductal adenocarcinoma (33.4%), distal cholangiocarcinoma (8.7%), ampullary carcinoma (7.1%), duodenal carcinoma (4.0%), or other (11.9%). Liver-directed therapies included hepatic resection alone (45.2%), hepatic resection plus ablation (11.1%), ablation alone (7.9%), transarterial chemoembolization (9.5%), and whole-liver irradiation (22.2%). The overall morbidity following liver-directed therapy was 34.1% and overall mortality was 2.4%. Patients undergoing staged liver-directed therapy (14.5%) versus simultaneous pancreaticoduodenectomy plus liver-directed therapy (7.0%) were more likely to develop a liver abscess (P < 0.05). Of those patients who developed complications, the majority (55.8%) were major (Clavien grade >or=3). Pancreaticoduodenectomy plus liver-directed therapy is associated with considerable morbidity. The incidence of hepatic abscess is increased in patients undergoing staged pancreaticoduodenectomy followed by liver-directed therapy.Keywords
This publication has 32 references indexed in Scilit:
- Liver metastases of neuroendocrine carcinomas: Interventional treatment via transarterial embolization, chemoembolization and thermal ablationEuropean Journal of Radiology, 2009
- Accelerated treatment using intensity‐modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinomaCancer, 2009
- Colorectal Liver MetastasesArchives of Surgery, 2008
- Local Recurrence After Laparoscopic Radiofrequency Ablation of Liver Tumors: An Analysis of 1032 TumorsAnnals of Surgical Oncology, 2008
- Surgical Therapy for Colorectal Metastases to the LiverJournal of Gastrointestinal Surgery, 2007
- Conformal Radiotherapy of the Dominant Liver MetastasisAmerican Journal of Clinical Oncology, 2006
- Phase II Trial of High-Dose Conformal Radiation Therapy With Concurrent Hepatic Artery Floxuridine for Unresectable Intrahepatic MalignanciesJournal of Clinical Oncology, 2005
- Prophylactic hepatic irradiation following curative resection of pancreatic cancerJournal of Hepato-Biliary-Pancreatic Surgery, 2005
- Combined Resection and Radiofrequency Ablation for Advanced Hepatic Malignancies: Results in 172 PatientsAnnals of Surgical Oncology, 2003
- Laparoscopic Radiofrequency Ablation of Neuroendocrine Liver MetastasesWorld Journal of Surgery, 2002